<DOC>
	<DOC>NCT00262080</DOC>
	<brief_summary>The purpose of this study is to determine if a subcutaneous dose of DX-88 (ecallantide; an investigational product) is safe and relieves symptoms of HAE in patients suffering from moderate to severe acute attacks of HAE.</brief_summary>
	<brief_title>Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<criteria>Age 10 and older Documented diagnosis of HAE, Type I or II Executed informed consent Presentation for treatment within 8 hours of patient recognition of moderate to severe HAE attack Receipt of investigational drug or device, other than DX88, within 30 days of treatment Receipt of noninvestigational C1INH (C1 esterase inhibitor) within 7 days of treatment Diagnostic of acquired angioedema, estrogendependent angioedema or drug induced angioedema Pregnancy or breastfeeding Patients who have received DX88 within 7 days of presentation for dosing in the Doubleblind Phase</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>